Prognostic significance of tumor subtypes in women with breast cancer according to stage: A population-based study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1070-1070
Author(s):  
Jose Pablo Leone ◽  
Julieta Leone ◽  
Ariel Osvaldo Zwenger ◽  
Carlos Teodoro Vallejo ◽  
Bernardo Amadeo Leone
Keyword(s):  
Breast Cancer ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Population Based ◽  
Her2 Status ◽  
Lower Grade ◽  
Breast Cancer Patients ◽  
Tumor Subtypes ◽  
Epidermal Growth ◽  
Stage 1

1070 Background: Tumor subtypes (TS) are an important prognostic tool in breast cancer patients (pts). However, with contemporary therapies the prognosis of different subtypes is unclear. Recently, the AJCC proposed to incorporate TS among other variables in the 8th edition of the staging manual. The aim of this study was to analyze differences in overall survival (OS) by TS according to stage compared with other factors. Methods: We evaluated women with microscopically confirmed invasive breast cancer between 2010 and 2013 with known estrogen receptor (ER) and progesterone receptor (PR) (together hormone receptor [HR]) status and human epidermal growth factor receptor 2 (HER2) status reported to the SEER program. Pts with other primary either before or after breast cancer were excluded. Pt characteristics were compared between TS. Univariate and multivariate analyses were performed to determine the effect of each variable on OS. Results: We included 166,054 pts. Median age was 60 years (range 18-108). Median follow-up was 21 months (range 1-48). TS distribution was: 72.5% HR+/HER2-, 10.8% HR+/HER2+, 4.8% HR-/HER2+ and 12% triple negative (TN). Pts with HR+/HER2- tumors were older, had lower grade and presented with earlier stage (all p < 0.0001). OS at 3 years for each subtype according to stage is shown in the table (p for interaction < 0.0001). These differences in OS by TS continued to be significant for each stage in multivariate analysis adjusted for age, race, grade, histology and marital status. Conclusions: In this cohort, we observed significant differences in pt characteristics according to TS. Although HR+/HER2- tumors had better clinicopathologic features, the HR+/HER2+ group had the best OS in most stages. OS was significantly different by TS in each of the 4 stages and these results remained significant in the multivariate model. Pts with TN stage 1 tumors had similar OS as pts with HR+/HER2+ stage 2 tumors. Our results support the incorporation of TS as part of the staging variables in breast cancer. [Table: see text]

Overall survival (OS) of men and women with breast cancer according to tumor subtype: A population-based study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1069-1069
Author(s):  
Julieta Leone ◽  
Ariel Osvaldo Zwenger ◽  
Bernardo Amadeo Leone ◽  
Carlos Teodoro Vallejo ◽  
Jose Pablo Leone
Keyword(s):  
Breast Cancer ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Stage I ◽  
Stage Iii ◽  
Her2 Status ◽  
Tumor Subtype ◽  
Men And Women ◽  
Tumor Subtypes ◽  
Risk Of Death

1069 Background: The outcomes of male breast cancer (MBC) and female breast cancer (FBC) according to tumor subtype are poorly known. Our group previously reported the prognostic significance of tumor subtypes in MBC. The aim of this study was to analyze differences in OS between MBC and FBC according to tumor subtype compared with other factors. Methods: We evaluated men and women with microscopically confirmed invasive breast cancer between 2010 and 2013 with known estrogen receptor (ER) and progesterone receptor (PR) (together hormone receptor [HR]) status and human epidermal growth factor receptor 2 (HER2) status reported to the SEER program. Patients (pts) with other primary either before or after breast cancer were excluded. Pt characteristics were compared between MBC and FBC. Univariate and multivariate analyses were performed to determine the effect of each variable on OS. Results: We included 1,187 MBC and 166,054 FBC pts. Median age for MBC was 65 years (range 26-97) and for FBC was 60 years (range 18-108). Median follow-up was 21 months (range 1-48) for both groups. OS at 3 years for MBC and FBC was 85.6% and 90.4%, respectively (p = 0.0002). MBC pts were more frequently ductal, had higher grade, presented with more advanced stage and were more often HR+/HER2- (all p < 0.0001). MBC had worse OS than FBC in HR+/HER2- (Hazard ratio [HaR] 1.5; p = 0.0005), HR+/HER2+ (HaR 2.8; p < 0.0001) and triple negative (TN) (HaR 4.3; p < 0.0001) (p for interaction < 0.02). MBC had significantly worse OS than FBC in stage I and II, but similar OS in stage III and IV (p for interaction < 0.01). In multivariate analysis adjusted for age, race, grade, stage, surgery, radiation and marital status; HR+/HER2+ was the only subtype with significant differences in OS between MBC and FBC (HaR 2.0; p = 0.002). Conclusions: In this cohort, we observed significant differences in the distribution of tumor subtypes between MBC and FBC. OS was significantly different in both groups. Men had worse OS in stage I and II while similar OS in stage III and IV. There were significant differences in OS according to tumor subtype; compared with women, men with HR+/HER2+ tumors had twice the risk of death.

scholarly journals Ethnicity-Related Survival Analysis of Patients with Triple-Negative Breast Cancer

10.29007/f7fq ◽  
2019 ◽  
Author(s):  
Mohammad Owrang Ojaboni ◽  
Yasmine Kanaan ◽  
Robert Dewitty Jr
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Prognostic Significance ◽  
Growth Factor Receptor ◽  
Population Based ◽  
Lymph Node Status ◽  
Breast Cancer Patients ◽  
The Poor ◽  
Clinical Difference

Breast cancer prognostication is a vital element for providing effective treatment for breast cancer patients. Different types of breast cancer can be identified based on the existence or lack of certain receptors (i.e., estrogen, progesterone, her2 receptors). Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) expression. Existing studies suggest that TNBC patients tend to have worse prognosis compared to non-TNBC counterparts. The incidence of breast cancer and prognosis in women differ according to ethnicity. Given the poor prognosis of TNBC, cancer-related outcomes must be estimated accurately. Several factors responsible for the poor clinical outcomes observed in TNBC, including age, race/ethnicity, grade, tumor size, lymph node status among others, have been studied extensively. Available research data are not conclusive enough to make a convincing argument for or against a biological or clinical difference in TNBC patients based on these factors. This study was designed to investigate the effects of the ethnicity on breast cancer survivability among TNBC patients utilizing population-based Surveillance, Epidemiology, and End Results (SEER) data to confirm whether ethnicity factor has prognostic significance.

scholarly journals Trastuzumab administration in patients with breast cancer is associated with increased primary tumor expression of SH3BP2.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Signal Transduction ◽  
Growth Factor Receptor ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Binding Partner ◽  
Syk Kinase ◽  
Src Homology ◽  
Epidermal Growth ◽  
Tumor Expression

Trastuzumab, a monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2) is utilized for the treatment of human breast cancer (1, 2), but a complete understanding of how tumor signal transduction is modulated by trastuzumab treatment is lacking. By mining published and public microarray and gene expression data (3, 4) from the primary tumors of patients treated with trastuzumab, we found that the cell signaling intermediate and Src homology domain binding protein SH3BP2, also known as 3BP2, was among the genes most differentially expressed in the primary tumors of patients treated with trastuzumab. 3BP2 is a binding partner of the Syk kinase (5, 6); we recently described differential and increased expression of Syk in the tumors of breast cancer patients treated with trastuzumab (7); thus, trastuzumab may likely be associated with activation of Syk kinase signal transduction in primary tumors of patients with breast cancer.

scholarly journals The placental growth factor (PGF) is differentially expressed in the primary tumors of breast cancer patients treated with trastuzumab.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Placental Growth Factor ◽  
Differentially Expressed ◽  
Expression Data ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Epidermal Growth ◽  
The Brain

Trastuzumab, a monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2) is utilized for the treatment of human breast cancer (1, 2), but a complete understanding of how tumor signal transduction is modulated by trastuzumab treatment is lacking. By mining published and public microarray and gene expression data (3, 4) from the primary tumors of patients treated with trastuzumab, we found that the placental growth factor, encoded by PGF was among the genes most differentially expressed in the primary tumors of patients treated with trastuzumab, and expressed at lower levels in the tumors of patients treated with trastuzumab. Thus, the use of trastuzumab in patients with breast cancer is associated with increased expression of a growth factor that is chemotactic, angiogenic (5) and important for growth of blood vessels in the brain (6).

Sign in / Sign up

Export Citation Format

Share Document